Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa. -Sanofi + Drugs for Neglected Diseases initiative.
The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigational treatment for sleeping sickness, published in The Lancet Infectious Diseases medical journal
The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea.
Dr Victor Kande-Former Neglected Tropical Diseases Expert Advisor at the Ministry of Health of the DRC, principal investigator of the trial, and lead author of the Lancet article “Sleeping sickness is a nightmare disease that affects patients in some of the most remote settings in West and Central Africa, where distance from hospital can be measured in days. We are now on the cusp of a potential treatment that can be given in one day, in a single dose of three pills – this would be a revolution for doctors and communities.”
See- "Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase II/III trial"-The Lancet Infectious DiseasesPublished: November 29, 2022 Victor Kande Betu Kumeso,Wilfried Mutombo Kalonji,Sandra Rembry,Olaf Valverde Mordt,Digas Ngolo Tete,Adeline Prêtre and others.The Lancet Infectious Diseases.Published: November 29, 2022.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins